As an imaging biomarker, FAP is also upregulated in actively remodeling tissues; therefore, the distinction between GBM and other neurological inflammatory or autoimmune diseases relies on clinical manifestations and multimodal imaging, including MRI. The gene discussed is FAP; the disease is autoimmune disease.